Challenges in COVID-19 Biospecimen Research

What are COVID-19 Biospecimens?

Since 2019 the COVID-19 outbreak has caused millions of fatalities and premature mortalities across the globe. Therefore, assessing the spread and severity of the disease outbreak, COVID-19 was declared a public health emergency of international concern on 30 January 2020. Scientists worldwide strive for active research by utilizing COVID-19 biospecimens to develop newer therapeutics and diagnostics to put an end to the global pandemic.

COVID-19 biospecimens are the human samples collected from individuals suspected or infected with COVID-19. Human biospecimens of COVID-19 comprise samples of serum, plasma, whole blood, oropharyngeal, and nasopharyngeal secretion collected during the disease screening process. The specimens are the residual samples after diagnostic reporting collected, processed, and stored in sophisticated biobanks functional across the globe. In short, COVID-19 biospecimens act as in-vitro Coronavirus models for research. Read our latest blog to learn more about human biospecimens for research: https://centralbiohub.de/blogs/human-biospecimens

Challenges of Research onCOVID-19 Biospecimens.

The high incidence of COVID-19cases calls for an urgent need for strengthening research on the broader landscape to comprehend the pathogenesis and infection biology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Studies on human biospecimens from COVID-19 patients can offer a deeper understanding of the disease and can lead to accelerated research. However, with the urge to have a wide range of human biospecimens, there are many challenges and risks for COVID-19 biospecimen research. The predominant challenges in research on COVID-19 biospecimens are detailed below:

Uncertain sample quality: In most cases, the research samples are procured through the brokers or biospecimen companies who may fail to prove the certification of the human biospecimen collection, biobanking, and chain of custody. It can directly influence the research outcome and validity as it is vital for the researchers to verify the sample’s authenticity and approval from IRB protocol.

Accuracy of sample information: Human biospecimens always come with associated details regarding the patient’s clinical condition, diagnosis, laboratory reports, etc. It allows better characterization of biosamples for in-depth analysis. In some cases, the specimen provider offers incomplete data or findings uncertified by medical practitioners that are not acceptable as per the quality standards.

Central BioHubUnleashes the Largest Inventory of COVID-19 Research Samples.

Boost up global COVID-19 research. Central BioHub brings you a fresh stock of COVID-19 biospecimens collected from suspected and clinically confirmed patients across the globe. Resolving all the potential challenges in coronavirus research, Central BioHuboffers a plethora of well-annotated, accurately screened, and well preservedhuman biospecimens stored in biobanks across the globe. Above all, every sample can be readily procurable online through the most innovative human biospecimen marketplace without any hassle. Click here to explore the COVID-19 inventory of Central BioHub: https://centralbiohub.de/biospecimens/COVID-19

Moreover, Central BioHub delivers you COVID-19 biosamples that are ethically obtained, adhering to strict IRB protocols, and precisely handled to optimize diagnostic yield and enhance life science discovery. Besides, our scientific experts at Central BioHub assist you in every step of biospecimens procurement.

What are COVID-19 Biospecimens?

Since 2019 the COVID-19 outbreak has caused millions of fatalities and premature mortalities across the globe. Therefore, assessing the spread and severity of the disease outbreak, COVID-19 was declared a public health emergency of international concern on 30 January 2020. Scientists worldwide strive for active research by utilizing COVID-19 biospecimens to develop newer therapeutics and diagnostics to put an end to the global pandemic.

COVID-19 biospecimens are the human samples collected from individuals suspected or infected with COVID-19. Human biospecimens of COVID-19 comprise samples of serum, plasma, whole blood, oropharyngeal, and nasopharyngeal secretion collected during the disease screening process. The specimens are the residual samples after diagnostic reporting collected, processed, and stored in sophisticated biobanks functional across the globe. In short, COVID-19 biospecimens act as in-vitro Coronavirus models for research. Read our latest blog to learn more about human biospecimens for research: https://centralbiohub.de/blogs/human-biospecimens

Challenges of Research onCOVID-19 Biospecimens.

The high incidence of COVID-19cases calls for an urgent need for strengthening research on the broader landscape to comprehend the pathogenesis and infection biology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Studies on human biospecimens from COVID-19 patients can offer a deeper understanding of the disease and can lead to accelerated research. However, with the urge to have a wide range of human biospecimens, there are many challenges and risks for COVID-19 biospecimen research. The predominant challenges in research on COVID-19 biospecimens are detailed below:

Uncertain sample quality: In most cases, the research samples are procured through the brokers or biospecimen companies who may fail to prove the certification of the human biospecimen collection, biobanking, and chain of custody. It can directly influence the research outcome and validity as it is vital for the researchers to verify the sample’s authenticity and approval from IRB protocol.

Accuracy of sample information: Human biospecimens always come with associated details regarding the patient’s clinical condition, diagnosis, laboratory reports, etc. It allows better characterization of biosamples for in-depth analysis. In some cases, the specimen provider offers incomplete data or findings uncertified by medical practitioners that are not acceptable as per the quality standards.

Central BioHubUnleashes the Largest Inventory of COVID-19 Research Samples.

Boost up global COVID-19 research. Central BioHub brings you a fresh stock of COVID-19 biospecimens collected from suspected and clinically confirmed patients across the globe. Resolving all the potential challenges in coronavirus research, Central BioHuboffers a plethora of well-annotated, accurately screened, and well preservedhuman biospecimens stored in biobanks across the globe. Above all, every sample can be readily procurable online through the most innovative human biospecimen marketplace without any hassle. Click here to explore the COVID-19 inventory of Central BioHub: https://centralbiohub.de/biospecimens/COVID-19

Moreover, Central BioHub delivers you COVID-19 biosamples that are ethically obtained, adhering to strict IRB protocols, and precisely handled to optimize diagnostic yield and enhance life science discovery. Besides, our scientific experts at Central BioHub assist you in every step of biospecimens procurement.

Article source: https://article-realm.com/article/Sports-Recreation/23130-Challenges-in-COVID-19-Biospecimen-Research.html